Literature DB >> 24584910

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.

Toby A Eyre1, Sarah Gooding, Ishita Patel, Niall Moore, Chris Hatton, Graham P Collins.   

Abstract

Gemcitabine is a nucleoside analogue used widely across haemato-oncology. Side effects are generally predictable, and typically consist of cytopenia, nausea, and infection. As the present case clearly demonstrates, gemcitabine is in rare cases associated with life-threatening large vessel vasculitis, which can involve the aorta. It is important to consider gemcitabine-induced vasculitis in non-specifically unwell patients with raised inflammatory markers and fever of unknown origin, with or without signs of vascular compromise. Early recognition, cessation of gemcitabine therapy, and high-dose steroids are critical for a good outcome. PET CT is valuable to diagnose large vessel vasculitis and monitor treatment response.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24584910     DOI: 10.1007/s12185-014-1555-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy.

Authors:  M J Banach; G A Williams
Journal:  Arch Ophthalmol       Date:  2000-05

2.  Sonography and CT of vasculitis during gemcitabine therapy.

Authors:  Nadine Bendix; Bernhard Glodny; Maria Bernathova; Gerd Bodner
Journal:  AJR Am J Roentgenol       Date:  2005-03       Impact factor: 3.959

3.  Cutaneous vasculitis associated with gemcitabine therapy.

Authors:  F Corella; J Dalmau; E Roé; X García-Navarro; A Alomar
Journal:  Clin Exp Dermatol       Date:  2009-01       Impact factor: 3.470

4.  Cutaneous T-cell lymphomas. Summary of the Mycosis Fungoides Cooperative Group-National Cancer Institute Workshop.

Authors:  S I Lamberg; P A Bunn
Journal:  Arch Dermatol       Date:  1979-09

5.  [Cerebral vasculitis associated with gemcitabine].

Authors:  P Schmorl; A Heer-Sonderhoff; R Vosshenrich; S Conrad
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

6.  Vasculitis due to gemcitabine.

Authors:  A M C J Voorburg; F T van Beek; P H Th J Slee; C A Seldenrijk; F M N H Schramel
Journal:  Lung Cancer       Date:  2002-05       Impact factor: 5.705

7.  Gemcitabine-associated large vessel vasculitis presenting as fever of unknown origin.

Authors:  Laura B Ramsay; Michael P Stany; Jess D Edison; Sarah A Bernstein; Kevin E Schlegal; Chad A Hamilton
Journal:  J Clin Rheumatol       Date:  2010-06       Impact factor: 3.517

8.  Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.

Authors:  L Vénat-Bouvet; K Ly; J C Szelag; J Martin; J L Labourey; D Genet; N Tubiana-Mathieu
Journal:  Anticancer Drugs       Date:  2003-11       Impact factor: 2.248

9.  Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer.

Authors:  John P Geisler; Daniel F Schraith; Kelly J Manahan; Joel I Sorosky
Journal:  Gynecol Oncol       Date:  2004-02       Impact factor: 5.482

10.  Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder.

Authors:  M Birlik; S Akar; E Tuzel; F Onen; E Ozer; M Manisali; Z Kirkali; N Akkoc
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-27       Impact factor: 4.553

View more
  2 in total

Review 1.  Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.

Authors:  Ezgi Guler; Daniel A Smith; Bhanusupriya Somarouthu; Rahul Gujrathi; Nikhil H Ramaiya; Sree Harsha Tirumani
Journal:  Abdom Radiol (NY)       Date:  2020-03

2.  Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review.

Authors:  Kirsi Taimen; Samu Heino; Ia Kohonen; Heikki Relas; Riikka Huovinen; Arno Hänninen; Laura Pirilä
Journal:  Rheumatol Adv Pract       Date:  2020-02-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.